Cyta Therapeutics, Inc. (Cyta) is a pre-clinical stage company developing therapeutics for obesity, NASH and other liver diseases. We are leveraging a novel polymer nanoparticle delivery platform that targets the liver, called IntelliGel, developed in the laboratory of Professor S. Thayumanavan at the University of Massachusetts, Amherst. The company’s lead program is a therapeutic (CYTA-001) being developed for a first indication of obesity. CYTA-001 is an encapsulated potent thyromimetic which has shown significant weight loss in a Diet Induced obesity-NASH animal model. Cyta is building a pipeline based on its ability to delivery highly potent drug assets with increased safety and efficacy. We have raised seed funding and conducted research collaborations with pharma companies. Currently, Cyta is seeking to raise capital to bring its lead program into the clinic.
View Top Employees from Cyta Therapeutics| Website | https://cytatx.com/ |
| Revenue | $1 million |
| Employees | 2 (2 on RocketReach) |
| Founded | 2015 |
| Industry | Biotechnology Research, Business Services General, Business Services |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies |
Looking for a particular Cyta Therapeutics employee's phone or email?
Cyta Therapeutics Questions
The Cyta Therapeutics annual revenue was $1 million in 2024.
Bonnie Fendrock is the Co-Founder and Chief Executive Officer of Cyta Therapeutics.
2 people are employed at Cyta Therapeutics.
Cyta Therapeutics is based in Boston, Massachusetts.
The NAICS codes for Cyta Therapeutics are [54, 541714, 54171, 5417, 541].
The SIC codes for Cyta Therapeutics are [87, 873].
Top Cyta Therapeutics Employees
-
55+
-
45+
Related Companies
